PD-L1

You have access
⁸⁹Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
Sarah R. Verhoeff, Pim P. van de Donk, Erik H.J.G. Aarntzen, Sjoukje F. Oosting, Adrienne H. Brouwers, Iris H.C. Miedema, Jens Voortman, Willemien C. Menke-van der Houven van Oordt, Ronald Boellaard, Dennis Vriens, Marije Slingerland, Rick Hermsen, Ilse van Engen-van Grunsven, Sandra Heskamp and Carla M.L. van Herpen

Journal of Nuclear Medicine October 1, 2022, 63 (10) 1523-1530; DOI: https://doi.org/10.2967/jnumed.121.263470
You have access
Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats
Alizée Bouleau, Hervé Nozach, Steven Dubois, Dimitri Kereselidze, Céline Chevaleyre, Cheng-I Wang, Michael J. Evans, Vincent Lebon, Bernard Maillère and Charles Truillet

Journal of Nuclear Medicine August 1, 2022, 63 (8) 1259-1265; DOI: https://doi.org/10.2967/jnumed.121.262967
You have access
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
Justin Ferdinandus, Wolfgang P. Fendler, Katharina Lueckerath, Christoph Berliner, Sabine Kurzidem, Eva Hadaschik, Joachim Klode, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Ken Herrmann, Juergen C. Becker and Selma Ugurel

Journal of Nuclear Medicine March 1, 2022, 63 (3) 396-398; DOI: https://doi.org/10.2967/jnumed.121.262344
You have access
⁸⁹Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
Kyung-Ho Jung, Jin Won Park, Jin Hee Lee, Seung Hwan Moon, Young Seok Cho and Kyung-Han Lee

Journal of Nuclear Medicine May 10, 2021, 62 (5) 656-664; DOI: https://doi.org/10.2967/jnumed.120.250720
You have access
PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
Gaochao Lv, Xiaorong Sun, Ling Qiu, Yan Sun, Ke Li, Qingzhu Liu, Qi Zhao, Songbing Qin and Jianguo Lin

Journal of Nuclear Medicine January 1, 2020, 61 (1) 117-122; DOI: https://doi.org/10.2967/jnumed.119.226712
Open Access
Early Phase I Study of a ^99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer
Yan Xing, Gitasha Chand, Changchun Liu, Gary J.R. Cook, Jim O’Doherty, Lingzhou Zhao, Nicholas C.L. Wong, Levente K. Meszaros, Hong Hoi Ting and Jinhua Zhao

Journal of Nuclear Medicine September 1, 2019, 60 (9) 1213-1220; DOI: https://doi.org/10.2967/jnumed.118.224170
You have access
Synthesis and Biologic Evaluation of a Novel ¹⁸F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly, R. Adam Smith, Paul Morin, Daša Lipovšek, Jochem Gokemeijer, Daniel Cohen, Virginie Lafont, Tritin Tran, Erin L. Cole, Martin Wright, Joonyoung Kim, Adrienne Pena, Daniel Kukral, Douglas D. Dischino, Patrick Chow, Jinping Gan, Olufemi Adelakun, Xi-Tao Wang, Kai Cao, David Leung, Samuel J. Bonacorsi and Wendy Hayes

Journal of Nuclear Medicine March 1, 2018, 59 (3) 529-535; DOI: https://doi.org/10.2967/jnumed.117.199596
You have access
Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging
Aaron T. Mayer, Arutselvan Natarajan, Sydney R. Gordon, Roy L. Maute, Melissa N. McCracken, Aaron M. Ring, Irving L. Weissman and Sanjiv S. Gambhir

Journal of Nuclear Medicine April 1, 2017, 58 (4) 538-546; DOI: https://doi.org/10.2967/jnumed.116.177659
You have access
Molecular Imaging of Immunotherapy Targets in Cancer
Emily B. Ehlerding, Christopher G. England, Douglas G. McNeel and Weibo Cai

Journal of Nuclear Medicine October 1, 2016, 57 (10) 1487-1492; DOI: https://doi.org/10.2967/jnumed.116.177493

Main menu

User menu

Search

PD-L1